Speciality Medicines Ltd

Speciality Medicines Limited (SPML) announced its audited standalone financial results for the half-year and full financial year ended March 31, 2026. For the full year, the company reported Revenue from Operations of ₹7,528.51 Lakh and a Profit for the period of ₹1,303.29 Lakh. For the half-year ended March 31, 2026, Revenue from Operations stood at ₹4,478.34 Lakh, with a Profit for the period of ₹818.27 Lakh. The Board of Directors approved these results, along with the audited standalone financial statements, and noted the utilization of Initial Public Issue (IPO) proceeds in line with the prospectus. The Auditor's Report was issued with an unmodified opinion.

Speciality Medicines Limited (SPML) announced the outcome of its Board Meeting held on May 28, 2026. The Board approved and took on record the Audited Standalone Financial Statements and Results for the half-year and financial year ended March 31, 2026, along with the Auditor's Report, which had an unmodified opinion. For the financial year ended March 31, 2026, the company reported Revenue from Operations of ₹7,528.51 Lakh and a Profit for the period of ₹1,303.29 Lakh. The Board also noted the utilization of Initial Public Issue (IPO) proceeds for the same period, confirming adherence to the objects stated in the prospectus.

Speciality Medicines Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited standalone financial statements and results for the financial year ended March 31, 2026. The trading window for insiders has been closed from April 1, 2026, and will reopen 48 hours after the board meeting concludes.

Niraj Shah acquired shares of Speciality Medicines Limited, as disclosed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition involved 87,85,796 equity shares of ₹10 each, amounting to ₹8,78,57,960. After the acquisition, Niraj Rajnikant Shah holds 5,47,000 shares, representing 6.22% of the total share/voting capital of Speciality Medicines Limited.

Speciality Medicines Ltd. announced that its Board of Directors, in a meeting held on April 28, 2026, approved several key appointments and authorizations. The board appointed M/s. Hardik Jetani & Associates as the Secretarial Auditor for the financial year 2025-26. Additionally, M/s. Rahul Mistri and Co., Chartered Accountants, were appointed as the Internal Auditor for three financial years, from FY 2025-26 to FY 2027-28. The Board also authorized Key Managerial Personnel to determine the materiality of events and information for stock exchange disclosures and reviewed related party transaction recommendations from the Audit Committee.

Speciality Medicines Ltd has updated the contact details of its Key Managerial Personnel (KMP) responsible for determining the materiality of events and making disclosures to the stock exchanges. This action is in compliance with Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors authorized Mr. Parthkumar Babulal Goyani (Chairman and Managing Director) and Ms. Anita Kumawat (Company Secretary & Compliance Officer) for these roles during a board meeting held on April 28, 2026. The contact information, including phone and email, for Mr. Goyani is provided. The details are also available on the company's website.

The Board of Directors of Speciality Medicines Ltd (SPML) met on April 28, 2026, and approved several key items. These include the appointment of M/s. Hardik Jetani & Associates as Secretarial Auditor for FY 2025-26 and M/s. Rahul Mistri and Co. as Internal Auditor for three financial years from FY 2025-26 to FY 2027-28. Additionally, the Board authorized Key Managerial Personnel (KMP) to determine the materiality of events and make disclosures to stock exchanges as per Regulation 30(5) of SEBI Listing Regulations. The Board also reviewed and acknowledged the Audit Committee's recommendations and approvals regarding related party transactions.

Speciality Medicines Ltd (SPML) has finalized a commercial arrangement with an international entity for distributing, marketing, and selling the company's products. The order is valued at USD 2 million (approximately ₹18.8 Crores) and is subject to mutually agreed terms and conditions. This arrangement is expected to enhance the company’s distribution network and revenue visibility. The order has been received from an International entity. The promoters have no interest in the order, and it is not a related party transaction.

Speciality Medicines Ltd (SPML) has finalized a commercial arrangement with an international entity for distributing, marketing, and selling its products. The order is valued at USD 1.5 million (approximately ₹14 Crores). This arrangement is expected to enhance the company’s distribution network and revenue visibility. The order has been received from an international entity, with no interest from promoters or related parties.

Speciality Medicines Ltd has responded to a stock exchange clarification regarding the significant movement in its share price. The company stated that it consistently complies with SEBI LODR Regulations and promptly discloses all material information. Based on current information, the company believes there are no undisclosed material events or developments. It attributes the price movement to market-driven factors, general market conditions, and investor sentiment, and assures continued compliance with disclosure norms.